肝细胞癌临床表现与结局的种族和民族差异
该回顾性研究纳入2008年1月至2017年7月美国2个大型医疗系统1117例肝细胞癌患者,分析种族和民族在分期、治疗及生存上的差异。西班牙裔和黑人患者较白人更少在早期诊断,西班牙裔早期患者更少接受治愈性治疗;校正保险、Child-Pugh分级、BCLC分期和治疗后,黑人死亡率更高而西班牙裔更低。
要点
- 西班牙裔(OR 0.75;95%CI 0.55-1.00)和黑人(OR 0.74;95%CI 0.56-0.98)较白人更少诊断早期肝细胞癌。
- 早期肝细胞癌中,西班牙裔较白人更少接受治愈性治疗(OR 0.58;95%CI 0.36-0.91)。
- 校正混杂因素后,黑人死亡率高于白人(HR 1.12;95%CI 1.10-1.14),西班牙裔低于白人(HR 0.83;95%CI 0.74-0.94)。
核心结论
- 肝细胞癌结局的种族和民族差异与早期肿瘤检出及治愈性治疗接受度差异相关,这些因素是改善结局和缩小差异的干预靶点。
研究设计与样本
- 回顾性研究,纳入2008年1月至2017年7月美国2个大型医疗系统诊断的1117例肝细胞癌患者。
主要发现
- 1117例中白人35.9%、黑人34.3%、西班牙裔29.7%;463例(41.5%)诊断早期肝细胞癌(巴塞罗那临床肝癌分期0/A期),322例(28.8%)接受治愈性治疗。
- 西班牙裔(OR 0.75;95%CI 0.55-1.00)和黑人(OR 0.74;95%CI 0.56-0.98)较白人更少诊断早期肝细胞癌。
- 早期肝细胞癌中,西班牙裔较白人更少接受治愈性治疗(OR 0.58;95%CI 0.36-0.91);黑人较白人亦更少接受治愈性治疗但未达统计学显著(OR 0.66;95%CI 0.43-1.03)。
- 黑人和西班牙裔中位生存期分别为10.6个月和14.4个月,均短于白人的16.3个月。
- 校正医疗保险类型、Child-Pugh分级、巴塞罗那临床肝癌分期和肝细胞癌治疗后,黑人死亡率高于白人(HR 1.12;95%CI 1.10-1.14),西班牙裔低于白人(HR 0.83;95%CI 0.74-0.94)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Racial and ethnic minorities are reported to have higher mortality related to hepatocellular carcinoma (HCC) than non-Hispanic whites. However, it is not clear whether differences in tumor characteristics or liver dysfunction among racial or ethnic groups affect characterization of causes for this disparity. We aimed to characterize racial and ethnic differences in HCC presentation, treatment, and survival. METHODS: We performed a retrospective study of patients diagnosed with HCC from January 2008 through July 2017 at 2 large health systems in the United States. We used multivariable logistic regression and Cox proportional hazard models to identify factors associated with receipt of curative therapy and overall survival. RESULTS: Among 1117 patients with HCC (35.9% white, 34.3% black, 29.7% Hispanic), 463 (41.5%) were diagnosed with early stage HCC (Barcelona Clinic Liver Cancer stage 0/A) and 322 (28.8%) underwent curative treatment. Hispanic (odds ratio [OR], 0.75; 95% CI, 0.55-1.00) and black patients (OR, 0.74; 95% CI, 0.56-0.98) were less likely to be diagnosed with early stage HCC than white patients. Among patients with early stage HCC, Hispanics were less likely to undergo curative treatment than whites (OR, 0.58; 95% CI, 0.36-0.91). Black patients with early stage HCC were also less likely to undergo curative treatment than white patients, but this difference was not statistically significant (OR, 0.66; 95% CI, 0.43-1.03). Black and Hispanic patients had shorter median survival times than white patients (10.6 and 14.4 mo vs 16.3 mo). After adjusting for type of medical insurance, Child-Pugh class, Barcelona Clinic Liver Cancer stage, and receipt of HCC treatment, black patients had significantly higher mortality (hazard ratio, 1.12; 95% CI, 1.10-1.14) and Hispanic patients had lower mortality (hazard ratio, 0.83; 95% CI, 0.74-0.94) than white patients. CONCLUSIONS: In a retrospective study of patients diagnosed with HCC, we found racial/ethnic differences in outcomes of HCC to be associated with differences in detection of tumors at early stages and receipt of curative treatment. These factors are intervention targets for improving patient outcomes and reducing disparities.
引用
- Rich NE, Hester C, Odewole M, et al. Racial and Ethnic Differences in Presentation and Outcomes of Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2018. PMID: 29859983. doi:10.1016/j.cgh.2018.05.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。